---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-017919"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:16:30.044136+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Crinetics Q1 net loss $46M; paltusotine Phase 3 PATHFNDR-1 data on track for Q3 2023

## Summary
- Net loss $46.0M for Q1 2023 vs $34.6M in Q1 2022; R&D expenses $38.5M, G&A $12.2M.
- Paltusotine PATHFNDR-1 (acromegaly) enrollment complete; topline data expected Q3 2023.
- PATHFNDR-2 enrollment target increased to up to 98; topline data expected Q1 2024.
- Phase 2 open-label study of paltusotine in carcinoid syndrome; preliminary data expected Q4 2023.
- CRN04777 Phase 2 study for congenital hyperinsulinism on clinical hold; additional info to be submitted to FDA.

## SEC filing metadata
- accession: 0000950170-23-017919
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017023017919/0000950170-23-017919-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017023017919/crnx-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-017919
- JSON: https://secwatch.observer/filing/0000950170-23-017919.json
- Plain text: https://secwatch.observer/filing/0000950170-23-017919.txt

## Key facts
- Earnings Releases
  Crinetics Pharmaceuticals, Inc. reported the first quarter ended March 31, 2023 results: revenue $2.7 million, net income Net loss of $46.0 million.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $2.7 million
  - Net income: Net loss of $46.0 million
  - Result: reported results
  source text: for the three months ended March 31, 2023, compared to $8.7 million for the same period in 2022. The increase was primarily attributable to an increase in personnel costs of $2.7 million and an increase in other corporate expenditures of $0.8 million. • Net loss for the three months ended March 31, 2023 was $46.0 million, compared to a net loss of $34.6 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000095017023017919/0000950170-23-017919-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.